Viking Therapeutics Launches VK2735 Clinical Trial for Obesity
Study to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735
Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens to be Evaluated
Viking Therapeutics, Inc. (NASDAQ: VKTX), a clinical-stage biopharmaceutical company, has announced an exciting development in its research efforts aimed at treating obesity. The company has initiated a clinical trial focusing on the maintenance dosing of VK2735, a groundbreaking dual agonist that targets crucial pathways for managing metabolic disorders.
This newly launched trial is designed to explore various dosing regimens for VK2735 after patients achieve initial weight loss. The study will evaluate both oral and subcutaneous formulations to determine the most effective methods for maintaining weight loss. VK2735 has garnered attention for its potential to significantly benefit those facing obesity, a condition that affects millions.
The maintenance dosing study is a Phase 1, randomized, double-blind, placebo-controlled trial set to involve around 180 healthy adults with obesity. These individuals will initially receive weekly subcutaneous doses of VK2735 or a placebo for 19 weeks. Following this period, they will be transitioned to different maintenance options, such as monthly or daily doses, to assess which regimens can help sustain their weight loss.
Brian Lian, Ph.D., the chief executive officer of Viking Therapeutics, expressed optimism about the potential findings of this study. He noted, "This study will provide key information to help identify future VK2735 maintenance regimens. Flexible dosing options including potential weekly or monthly subcutaneous administration, as well as potential daily or weekly oral administration, are important differentiating features of our program that could facilitate improved treatment persistence." The importance of adherence to therapy cannot be underestimated, he emphasized, as it increases the likelihood of achieving long-term benefits, including enhanced physical function and lower cardiovascular risk.
Moreover, the company is actively engaged in two additional Phase 3 trials, VANQUISH-1 and VANQUISH-2, which are investigating the efficacy of VK2735. These trials are significant as they aim to provide deeper insights into how effectively VK2735 can treat patients suffering from obesity and related conditions.
In VANQUISH-1, around 4,500 adults without type 2 diabetes will be recruited, while VANQUISH-2 is designed to include approximately 1,100 adults who do have type 2 diabetes. Participants in both trials will be randomly assigned to receive different doses of VK2735 or placebo over 78 weeks.
Understanding GLP-1 and Dual GLP-1/GIP Agonists
At the core of VK2735’s mechanism are its interactions with glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The activation of the GLP-1 receptor leads to positive outcomes such as reducing insulin resistance, appetite, and overall body weight. Recent approvals of therapies like semaglutide, marketed under brands like Ozempic and Wegovy, have shown the effectiveness of GLP-1 agonists.
Additionally, research has shifted towards exploring the combined activation of both GLP-1 and GIP receptors, which may offer enhanced therapeutic options for patients. Tirzepatide, another dual receptor agonist, reflects this promising avenue of research.
About Viking Therapeutics, Inc.
Founded with the mission to pioneer first-in-class therapies, Viking Therapeutics emphasizes innovation in addressing metabolic and endocrine disorders. Their existing compounds aim to transform treatment landscapes for conditions like obesity, and their research is rooted in a deep understanding of metabolic pathways.
In addition to VK2735, Viking is advancing other promising therapies. For instance, VK2809 is an oral small molecule designed to target thyroid hormone receptor beta, delivering mainstream hope for managing lipid and metabolic disorders. Past results from clinical trials involving VK2809 have shown significant reductions in LDL cholesterol and liver fat content.
Furthermore, Viking's initiatives extend to developing VK0214, which focuses on addressing rare diseases. This compound has demonstrated positive outcomes in early trials aimed at reducing very long-chain fatty acids in patients with X-linked adrenoleukodystrophy (X-ALD), reflecting on the company’s broad commitment to various therapeutic challenges.
For more information about Viking Therapeutics, visit www.vikingtherapeutics.com.
Frequently Asked Questions
What is the purpose of the VK2735 clinical trial?
The trial aims to explore various maintenance dosing regimens following initial weight loss achieved through VK2735 treatments.
How long will the VK2735 trial last?
The trial consists of an initial 19-week dosing period followed by maintenance phases that assess different dosing options.
Who can participate in the VK2735 trial?
Approximately 180 adults with obesity, classified as having a BMI of 30 kg/m2 or higher, are eligible for participation.
What other studies are Viking Therapeutics conducting?
Viking is conducting two Phase 3 studies, VANQUISH-1 and VANQUISH-2, evaluating the efficacy of VK2735 in larger groups.
What sets VK2735 apart from other obesity treatments?
VK2735's dual agonist properties and flexible dosing options may lead to enhanced adherence and sustained weight loss results in patients.
